KLA (NASDAQ:KLAC) reported quarterly earnings of $4.64 per share which beat the analyst consensus estimate of $4.52 by 2.65 percent. This is a 53.14 percent increase over earnings of $3.03 per share from the same period last year. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.04 billion by 2.16 percent. This is a 35.41 percent increase over sales of $1.54 billion the same period last year.
Seres Therapeutics’ Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
Seres Therapeutics Inc (NASDAQ: MCRB) has